Biogennix, an Irvine-based maker of bone graft substitutes, appointed Robert Baizer as its first chief financial officer.
“Robert is a great fit and brings strong business, medical device and financial leadership experience to our team,” Biogennix General Manager Michael Roux said in a statement.
Biogennix said its products have been used in more than 11,000 patients, including 5,000 in the past year.
Baizer has more than 25 years of financial experience. Most recently, he led a private equity group that worked with Qualcomm Inc. to develop a suite of wireless medical devices. He was a principal at private equity group Veraison Capital Management LLC.
